Abiopharma

News list

Rose Shawn Marshall 🟢 acquired 209.0K shares (1 derivative) of Nkarta, Inc. (NKTX) at $1.93 Transaction Date: Jan 06, 2026 | Filing ID: 007898

Full text

News bot Jan. 8, 2026, 10:52 p.m.
🔍 Rose Shawn Marshall (Executive)

Company: Nkarta, Inc. (NKTX)

Report Date: 2026-01-06
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 209,000
Detailed Transactions and Holdings:
- Acquired 70,000 shares of Common Stock (Direct)
  Date: 2026-01-06 | Code: A | equity_swap_involved: false | shares_owned_after: 70,000.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 139,000 shares of Stock Option (right to buy) at $1.93 per share (Derivative)
  Date: 2026-01-06 | Code: A | Expires: 2036-01-05 | equity_swap_involved: false | shares_owned_after: 139,000.00 | transaction_form_type: 4 | Footnotes: F2
Footnotes:
- F1: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
- F2: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2026.
- REMARKS: Chief Medical Officer, Head of Research & Development